Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Getting to goal in complex patients.

C Venkata1, S Ram

  • 1Texas Blood Pressure Institute, Dallas Nephrology Associates, University of Texas Southwestern Medical Center, Dallas, Texas 75235, USA. ramv@dneph.com

Clinical Cardiology
|March 8, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Axillary Ultrasound of Patients With and Without Breast Cancer: Sonographic Predictors of Malignancy.

European journal of breast health·2026
Same author

Contribution of the different Neisseria gonorrhoeae lipooligosaccharide structural variants to functional responses elicited by GMMA outer membrane vesicles.

NPJ vaccines·2025
Same author

Associations between breast implants and postpartum lactational mastitis in breastfeeding women: retrospective study.

BJOG : an international journal of obstetrics and gynaecology·2021
Same author

Spin-up conversion, exchange-interactions, and tailored magnetic properties in core-shell La<sub>2</sub>NiMnO<sub>6</sub>of small crystallites.

Nanotechnology·2021
Same author

Dr Norman M. Kaplan (1931-2020): a giant in the field of hypertension has departed.

European heart journal·2020
Same author

Green Synthesis of Cr<sup>3+</sup> Doped CaIn₂O₄-Carbon Hybrid Nanostructure and Its Light Absorption and Emission Properties.

Journal of nanoscience and nanotechnology·2019
Same journal

Strauss-Defined LBBB Identifies Patients With Improved Outcomes After CRT-D: A Comparative Cohort Study.

Clinical cardiology·2026
Same journal

Does Serum γKlotho Truly Provide Incremental Prognostic Value Beyond Established Risk Predictors in Multivessel Coronary Artery Disease?

Clinical cardiology·2026
Same journal

Associations of the C-Reactive Protein-Albumin-Lymphocyte Index, Red Cell Distribution Width-Albumin Ratio, and Blood Urea Nitrogen-Albumin Ratio With All-Cause and Cardiovascular Mortality Among Adults With Preclinical Heart Failure.

Clinical cardiology·2026
Same journal

Real-World National Databases Versus Hypothesis-Driven Cohort Studies: A Reply to the Critique on the TURK-HF Registry Design.

Clinical cardiology·2026
Same journal

Comment on Wang et al.: Unaddressed Multiple Comparisons Risk Inflating Type, Error in Cardiovascular Specialty Nursing Research.

Clinical cardiology·2026
Same journal

Methodological and Statistical Confounding in Comparing Patient-Reported Outcomes Between Cardioversion and Ablation for Atrial Fibrillation.

Clinical cardiology·2026
See all related articles

Complex hypertension management requires expanded definitions to include silent organ damage and high-risk groups. Aggressive blood pressure (BP) lowering, particularly with combination therapy, is crucial for halting vascular disease progression.

Area of Science:

  • Cardiology
  • Nephrology
  • Endocrinology

Background:

  • Complex hypertension traditionally defined by overt target organ damage.
  • Expanded definition includes patients with silent organ damage or high risk of developing it.
  • Significant number of hypertensive patients require specialized management.

Purpose of the Study:

  • To broaden the understanding of complex hypertension beyond manifest disease.
  • To highlight factors contributing to complex hypertension classification.
  • To emphasize the importance of aggressive blood pressure control and effective therapeutic strategies.

Main Methods:

  • Review of existing literature and clinical trial evidence.
  • Identification of factors defining complex hypertension (e.g., severe hypertension, comorbidities, high-risk populations).

Related Experiment Videos

  • Evaluation of therapeutic approaches focusing on goal blood pressure achievement.

    • Main Results:

    • Complex hypertension encompasses patients with silent organ damage and high-risk demographics (elderly, African Americans).
    • Severe hypertension, diabetes, renal insufficiency, coronary artery disease, and heart failure are key classifying factors.
    • Aggressive blood pressure lowering is essential for halting vascular disease progression.

    Conclusions:

    • Combination therapy, specifically calcium-channel blockers and angiotensin-converting enzyme inhibitors, demonstrates efficacy and organ protection in complex hypertension.
    • Achieving goal blood pressure is paramount, with drug selection prioritizing efficacy, organ protection, and tolerability.
    • Evidence supports favorable outcomes with combined therapies in managing complex hypertension.